Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

83.38CHF
19 Jan 2018
Change (% chg)

CHF0.48 (+0.58%)
Prev Close
CHF82.90
Open
CHF82.64
Day's High
CHF83.74
Day's Low
CHF82.64
Volume
6,506,723
Avg. Vol
4,419,214
52-wk High
CHF85.40
52-wk Low
CHF69.50

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.08
Market Cap(Mil.): CHF219,125.70
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.30

Financials

  Industry Sector
P/E (TTM): -- 33.09 17.86
EPS (TTM): -- -- --
ROI: -- 15.01 33.11
ROE: -- 16.57 17.05

Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

Jan 17 2018

UPDATE 1-Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH, Jan 17 Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

Jan 17 2018

Novartis gets U.S. priority review for Kymriah for adults with lymphoma

ZURICH, Jan 17 Novartis has been ‍granted priority review for its cell therapy Kymriah for adults with a form of lymphoma by the U.S. Food and Drug Administration, the Swiss drugmaker said on Wednesday, as it seeks to expand use of the treatment in multiple blood cancers.

Jan 17 2018

BRIEF-FDA accepts Novartis submission of biosimilar version of Humira

* SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA

Jan 16 2018

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

Jan 04 2018

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH, Jan 4 Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

Jan 04 2018

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

Jan 03 2018

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH, Jan 3 Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

Jan 03 2018

BRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch

* COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT

Dec 27 2017

UPDATE 1-Allergan says court affirms patent loss to Sandoz on eye drug

NEW YORK, Dec 22 Allergan Inc said on Friday that it had lost its appeal in a patent battle with Novartis AG over its Sandoz division's rival version of Allergan's Combigan eye drug and said it would file a petition to for a rehearing of the case.

Dec 22 2017

Earnings vs. Estimates